WaveMan
WaveMan · Company
CDNA · Caredx, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

CDNA CareDx (CDNA) Insider Trading, Ownership & Congress Trades

Healthcare Services · Services-medical laboratories · CIK 0001217234
Quote by TradingView
Form 144 · 15
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
133
13F, latest reported quarter
Conversions, 180 days
9
Codes C/M, not in net · $2.0M priced

What the filings say about CDNA

Insiders, 180 days
-$12.2M net sold
7 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$14.7M
15 notices

CareDx insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, CareDx, Inc. insiders sold a net $12.2M of stock across 130 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Novack Jeffrey Adam
Secretary and General Counsel
SELL
2026-08-06 SECtraded 2026-08-05
2,188
$101.0K
+48.0%
Context
  • 15 earlier Form 4 trades (code P or S) here by this insider (15 sales), the last on May 5, 2026.
  • The trade is 2.1% of the 106,575 shares held after it.
  • 5 other insiders sold within 30 days.
  • 133 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Secretary and General Counsel Novack Jeffrey Adam sold about $101.0K of CDNA on Aug 5, 2026; 5 other insiders sold within 30 days and 133 funds added in the latest 13F quarter.
Novack Jeffrey Adam
Secretary and General Counsel
SELL
2026-08-06 SECtraded 2026-08-05
500
$23.4K
+48.0%
Context
  • 15 earlier Form 4 trades (code P or S) here by this insider (15 sales), the last on May 5, 2026.
  • The trade is 0.5% of the 106,075 shares held after it.
  • 5 other insiders sold within 30 days.
  • 133 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Secretary and General Counsel Novack Jeffrey Adam sold about $23.4K of CDNA on Aug 5, 2026; 5 other insiders sold within 30 days and 133 funds added in the latest 13F quarter.
Bickerstaff George
Director
SELL
2026-08-06 SECtraded 2026-08-05
20,000
$925.7K
+48.0%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Mar 10, 2025.
  • The trade is 14.9% of the 134,061 shares held after it.
  • 5 other insiders sold within 30 days.
  • 133 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Bickerstaff George sold about $925.7K of CDNA on Aug 5, 2026; 5 other insiders sold within 30 days and 133 funds added in the latest 13F quarter.
Goldberg Michael
Director
SELL
2026-08-06 SECtraded 2026-08-04
44,700
$2.1M
+48.0%
Context
  • 7 earlier Form 4 trades (code P or S) here by this insider (7 sales), the last on Apr 11, 2022.
  • The trade is 72.4% of the 61,738 shares held after it.
  • 5 other insiders sold within 30 days.
  • 133 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Goldberg Michael sold about $2.1M of CDNA on Aug 4, 2026; 5 other insiders sold within 30 days and 133 funds added in the latest 13F quarter.
COURNOYER CHRISTINE
Director
SELL
2026-08-06 SECtraded 2026-08-04
16,000
$751.0K
+48.0%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on May 12, 2025.
  • The trade is 37.3% of the 42,943 shares held after it.
  • 5 other insiders sold within 30 days.
  • 133 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director COURNOYER CHRISTINE sold about $751.0K of CDNA on Aug 4, 2026; 5 other insiders sold within 30 days and 133 funds added in the latest 13F quarter.
130 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 125 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$12.2M over 180 days
-$3.9M over 90 days
below 73% of Healthcare Services
Congress
no House purchase disclosed in the last 12 months
Funds
133 funds bought in last quarter
more than 51% of Healthcare Services
Revenue
+13.8% year over year
more than 53% of Healthcare Services
Margin
-5.6% net margin
below 61% of Healthcare Services
Buybacks
$12.2M repurchased, FY to 2026-06-30
below 81% of Healthcare Services
Short interest
13.3% of the float short (float per yahoo 2026-10-26) · 4.6 days to cover · settled 2026-09-30
more than 89% of Healthcare Services
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch CDNA

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+370.1%12M
-3%+125%+253%+381%2025-102025-122026-022026-042026-062026-082026-10 2026-07-16 · Hanna John Walter JR sold $2.7M2026-08-04 · Goldberg Michael sold $2.1M2026-07-16 · Hanna John Walter JR sold $1.8M2026-06-29 · Hanna John Walter JR sold $1.2M2026-07-16 · Valantine Hannah sold $1.0M2026-08-05 · Bickerstaff George sold $925.7K2026-08-04 · COURNOYER CHRISTINE sold $751.0K2026-06-11 · Hanna John Walter JR sold $528.4K2026-06-15 · Hanna John Walter JR sold $424.9K2026-01-22 · Hanna John Walter JR sold $408.0K2026-06-15 · Valantine Hannah sold $279.7K2026-04-16 · Hanna John Walter JR sold $217.2K2026-01-15 · Hanna John Walter JR sold $213.8K2025-12-04 · Novack Jeffrey Adam sold $134.2K2026-05-15 · TORRES ARTHUR A sold $129.0K2026-06-04 · Hanna John Walter JR sold $116.0K2026-08-05 · Novack Jeffrey Adam sold $101.0K2026-02-03 · Novack Jeffrey Adam sold $91.3K2026-05-14 · TORRES ARTHUR A sold $85.7K2026-05-05 · Novack Jeffrey Adam sold $55.6K2025-11-07 · Novack Jeffrey Adam sold $41.7K2026-08-05 · Novack Jeffrey Adam sold $23.4K2025-12-04 · Novack Jeffrey Adam sold $5.6K2026-01-21 · Hanna John Walter JR sold $4.2K2026-07-16 · Valantine Hannah sold $3.7K2026-06-26 · Hanna John Walter JR sold $2.9K2026-08-17 · PETER MAAG filed to sell $423.1K2026-08-14 · PETER MAAG filed to sell $317.1K2026-08-13 · PETER MAAG filed to sell $329.5K2026-08-12 · PETER MAAG filed to sell $328.2K2026-08-11 · PETER MAAG filed to sell $333.9K2026-08-10 · ARTHUR TORRES filed to sell $200.5K2026-08-10 · PETER MAAG filed to sell $328.9K2026-08-07 · PETER MAAG filed to sell $1.3M2026-08-05 · GEORGE W BICKERSTAFF filed to sell $925.7K2026-08-05 · JEFFREY NOVACK filed to sell $126.6K2026-08-05 · PETER MAAG filed to sell $2.2M2026-08-04 · CHRISTINE COURNOYER filed to sell $1.5M2026-08-04 · Christine M. Cournoyer filed to sell $753.4K2026-08-04 · PETER MAAG filed to sell $3.6M2026-08-04 · MICHAEL D. GOLDBERG FAM TRUST filed to sell $2.1M2026-07-16 · HANNAH VALANTINE filed to sell $856.2K2026-07-16 · JOHN WALTER HANNA filed to sell $3.5M2026-06-29 · JOHN HANNA filed to sell $1.1M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns CDNA: institutional holders (13F)

13F holdings, latest reported quarter
BlackRock, Inc.
4,814,709 sh
$137.2M
STATE STREET CORP
2,468,858 sh
$70.4M
VANGUARD CAPITAL MANAGEMENT LLC
2,197,475 sh
$62.6M
DEERFIELD MANAGEMENT COMPANY, L.P.
1,997,618 sh
$56.9M
ARK Investment Management LLC
1,953,531 sh
$55.7M

Congress trades in CDNA

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

CDNA planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
PETER MAAG
Filed 2026-08-17
$423.1K
PETER MAAG
Filed 2026-08-14
$317.1K
PETER MAAG
Filed 2026-08-13
$329.5K
PETER MAAG
Filed 2026-08-12
$328.2K
PETER MAAG
Filed 2026-08-11
$333.9K

CDNA mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Invesco Biotechnology & Genome ETF
$14.2M position · as of 2026-07-31
5.0%
ARK Genomic Revolution ETF
$66.9M position · as of 2026-07-31
4.3%
ROBO Global Healthcare Technology and Innovation ETF
$1.9M position · as of 2026-07-31
2.7%
WPG Partners Select Small Cap Value Fund
$5.9M position · as of 2026-05-31
2.5%
BARON DISCOVERY FUND
$39.1M position · as of 2026-06-30
2.1%
Meridian Small Cap Growth Fund
$5.3M position · as of 2026-06-30
2.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
11 registered trials, 5 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
11
Not applicable
5 active
What changed recently
Forecasting Relapse Outcomes With AlloHeme-based Risk Detection in Post-Allo-HCT AML/MDS
2026-10-17 · Not Yet Recruiting → Enrolling By Invitation
,
Assessment of Chimerism and Relapse Post Bone Marrow/Hematopoietic Cell Transplant (HCT)
2026-10-17 · Active Not Recruiting → Completed
,
Assessment of Chimerism and Relapse Post Bone Marrow/Hematopoietic Cell Transplant (HCT)
2026-09-04 · Completion moved 2026-05-31 → 2026-10-15
,
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return · Dr Seeto
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2022
$12.8M
-$648.1K
$3.8M
-84%
-10%
2021
$7.1M
-$50.4K
$2.6M
-37%
+0%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $12.2M sold by insiders over 180 days, 133 funds added last quarter, $14.7M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
NTRACSTLPGNYHIMSWGSPRVATDOCAVAHGHADUSSERABDSX

CDNA financials

Revenue growth
+13.8%
XBRL, annual
Net margin
-5.6%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$458.1M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
+24.2%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
0.00x
LongTermDebt as filed 2024-09-30 (21 months older than the period end) (includes the current portion); equity 2026-06-30
Cash flow to debt
n/a
no debt to cover
Return on equity
+29.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
+22.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
+67.0%
operating income after a 3.6% effective tax rate, over LongTermDebt as filed 2024-09-30 (21 months older than the period end) (includes the current portion) plus average of 2025-06-30 and 2026-06-30 minus cash
Return on capital employed
+27.4%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
33.38x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
Enterprise value
$3.2B
market value at close 2026-10-26 on 2026-07-27 shares, plus LongTermDebt as filed 2024-09-30 (21 months older than the period end) (includes the current portion), minus cash 2026-06-30
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
0.34x
P/E over trailing EPS growth of 97%: four quarters to 2026-06-30 against the four to 2025-06-30
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$379.8M$333.8M$280.3M$321.8M
Operating income-$30.8M$40.8M-$203.4M-$77.2M
Net income-$21.4M$52.5M-$190.3M-$76.6M
EPS (diluted)-0.400.93-3.54-1.44
Operating cash flow$42.0M$38.0M-$18.4M-$25.2M
Cash$65.4M$114.7M$82.2M$89.9M
Buybacks$87.8M$522.0K$27.5M$642.0K
SEC XBRL, fiscal years, as known on 2026-10-28

CDNA Stock Sonar score 6/7 axes

Find similar shapesCompare

CDNA ranks highest on financial health (99th percentile) and profitability (96th), and lowest on insider conviction (13th), among Healthcare Services peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
96
Inputs
  • Return on equity+29.5% · 93 pct, sector of 70
  • Return on assets+22.7% · 98 pct, sector of 88
  • Return on invested capital+67.0% · 96 pct, universe of 1,069
  • Return on capital employed+27.4% · 99 pct, sector of 68
Financial health
100
Inputs
  • Debt to equity0.00x · 100 pct, sector of 61
  • Cash flow to debtno debt to cover
Growth
53
Inputs
  • Revenue growth, YoY+13.8% · 53 pct, sector of 87
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
13
Inputs
  • Net Form 4 buying (codes P and S), 180d-$12.2M · 25 pct, sector of 64
  • Insider buyers, 180d0 · 0 pct, sector of 64
Institutional and government
58
Inputs
  • Funds adding, latest quarter133 · 51 pct, sector of 73
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quarters$720K · 64 pct, universe of 1,063
Risk and compliance
17
Inputs
  • Short interest, % of float+13.3% · 19 pct, sector of 95
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+18.6% · 15 pct, sector of 72
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

CDNA filings, in plain words

Are CareDx insiders buying or selling CDNA?

In the 180 days to 2026-10-28, CareDx insiders were net sellers, a net $12.2M across purchases and sales reported on Form 4, by 7 sellers.

Are there planned insider sales of CDNA?

Yes. 15 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $14.7M of stock; the latest, by PETER MAAG, was filed 2026-08-17.

Read the full summary

In the 180 days to 2026-10-28, CareDx insiders were net sellers of CDNA, a net $12.2M across purchases and sales reported on Form 4 by 7 sellers. None of the 18 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 15 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $14.7M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies